Biofilms: Take my breath away
A lack of oxygen activates a pathway that causes the bacterial cell wall to break down, which, in turn, aids bacterial biofilm development.
- University of Nebraska Medical Center, United States
Although all bacteria are single-celled microorganisms, they display signs of multicellular behavior when they form communities known as biofilms. Within these communities, bacteria can sense cues from their environment, communicate with each other, differentiate into subpopulations, redistribute to form distinct architectures and cooperate in ways that enhance the ‘collective fitness’ of the biofilm.
At a molecular level, biofilm formation can be regarded as a complex developmental program that is controlled by multiple regulatory networks that effectively sense and respond to environmental signals (Moormeier and Bayles, 2017). Now, in eLife, Ameya Mashruwala, Adriana van de Guchte and Jeffrey Boyd of Rutgers University report how hypoxia (that is, a shortage of oxygen) influences the formation of biofilms in the bacterium Staphylococcus aureus (Mashruwala et al., 2017).
Staphylococcal biofilms are exposed to hypoxic conditions in a variety of environments, including when bacterial cell densities are high within the biofilm. A secreted sugar polymer called polysaccharide intercellular adhesin (PIA) is known to be involved in biofilm formation in some staphylococci, but very few clinical strains of S. aureus produce detectable levels of PIA in vitro. In fact, PIA is associated more with the protection of biofilms under conditions of high shear stress, rather than being a critical component of biofilm structure (Schaeffer et al., 2016; Foka et al., 2012; Weaver et al., 2012). Nevertheless, researchers have shown that hypoxia can increase PIA production, and thus biofilm formation, in strains that produce detectable levels of PIA (Cramton et al., 2001; Gotz, 2002).
Through a series of elegant experiments, Mashruwala et al. demonstrate that while hypoxia increases the biomass of the biofilm due to a decrease in cell respiration, the mechanism appears to be independent of PIA. Instead, they show that decreased respiration activates a pathway that results in cell lysis (that is, the breakdown of the cell wall that encloses the bacterium), which in turn leads to enhanced biofilm development.
Programmed cell death is thought to have evolved when multicellular organisms first originated. Since the individual cells that make up a multicellular organism are constrained for space and nutrients, they are limited in their capacity to multiply and must therefore cooperate to survive. Although a rather extreme form of cooperation, programmed cell death ensures that a multicellular body functions efficiently (Ameisen, 2002).
Similar to multicellular organisms, a bacterial biofilm may be viewed as a collection of cells that is confined within its extracellular matrix, which continuously controls the number of cells in the biofilm through regulated cell death and lysis mechanisms. This rather ruthless control of cell numbers has other benefits: for example, it increases the release of proteins and DNA from the bacteria, and these materials are then incorporated into the extracellular matrix in order to strengthen biofilm structure. Mashruwala et al. now demonstrate that hypoxia stimulates the release of proteins and DNA from the bacteria via cell lysis and that the depletion of extracellular protein and DNA (by protease or DNase treatments respectively) limits hypoxia mediated biofilm formation.
How does decreased respiration activate cell lysis? The critical component appears to be a signaling system called SrrAB, which is activated when an electron transporter called menaquinone remains chemically reduced. Once the SrrAB system has been activated, it increases the amount of the enzyme AtlA, a main player in cell destruction, and lowers the number of wall teichoic acids. In a healthy cell, the negative charge of the wall teichoic acids attracts protons and maintains an acidic microenvironment in the cell wall, which limits the activity and attachment of AtlA to the cell surface (Rice and Bayles, 2008; Biswas et al., 2012; Schlag et al., 2010). Mashruwala et al. also show that when the number of wall teichoic acids is low due to SrrAB activity, AtlA attaches more efficiently to the cell wall and is active enough to cause cell lysis.
How is this response ‘programmed’? In particular, is cell lysis an active response initiated by the cell following hypoxia, or is it a passive response due to an inability to adapt? The work of Mashruwala et al. clearly demonstrates that when various components of the programmed cell lysis pathway are inactive, cell lysis can be averted despite hypoxia. This suggests that cell lysis does not result from a general inability to adapt to hypoxia but rather is a bona fide programmed mechanism. However, outstanding questions remain. For instance, it is not clear why hypoxia only triggers lysis in some cells, despite all cells being genetically identical. Also, more research is needed to fully understand the relationship between cell lysis and programmed cell death during the development of a biofilm and how these processes overlap.
References
-
On the origin, evolution, and nature of programmed cell death: a timeline of four billion yearsCell Death and Differentiation 9:367–393.https://doi.org/10.1038/sj.cdd.4400950
-
Staphylococcus and biofilmsMolecular Microbiology 43:1367–1378.https://doi.org/10.1046/j.1365-2958.2002.02827.x
-
Molecular control of bacterial death and lysisMicrobiology and Molecular Biology Reviews 72:85–109.https://doi.org/10.1128/MMBR.00030-07
-
Role of staphylococcal wall teichoic acid in targeting the major autolysin AtlMolecular Microbiology 75:864–873.https://doi.org/10.1111/j.1365-2958.2009.07007.x
-
Fluid flow induces biofilm formation in Staphylococcus epidermidis polysaccharide intracellular adhesin-positive clinical isolatesApplied and Environmental Microbiology 78:5890–5896.https://doi.org/10.1128/AEM.01139-12
Article and author information
Author details
Publication history
Copyright
© 2017, Thomas et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,391
- views
-
- 191
- downloads
-
- 4
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Biofilms: Take my breath away
eLife 6:e25739.
https://doi.org/10.7554/eLife.25739
Further reading
-
A shortage of oxygen causes the bacteria Staphylococcus aureus to form biofilms that protect it from antibiotics.
-
- Immunology and Inflammation
- Microbiology and Infectious Disease
Pseudomonas aeruginosa (PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here, we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via single-cell sorting and paired-chain sequencing, identified the B cell receptor (BCR) variable region sequences that confer PcrV-specificity. We derived multiple high affinity anti-PcrV monoclonal antibodies (mAbs) from PcrV-specific B cells across three donors, including mAbs that exhibit potent anti-PA activity in a murine pneumonia model. This robust strategy for mAb discovery expands what is known about PA-specific B cells in pwCF and yields novel mAbs with potential for future clinical use.
